Equities

Coherus BioSciences Inc

Coherus BioSciences Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.69
  • Today's Change-0.09 / -5.06%
  • Shares traded1.87m
  • 1 Year change-68.47%
  • Beta0.5971
Data delayed at least 15 minutes, as of Jun 14 2024 21:00 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the research, development and commercialization of immunotherapies to treat cancer. Its immuno-oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable an immunologic response and enhance outcomes for patients with cancer. Casdozokitug is an anti-IL-27 antibody being evaluated in two ongoing clinical studies: a Phase I/II study in advanced solid tumors and a Phase II study in hepatocellular carcinoma. CHS-114 is an ADCC-enhanced anti-CCR8 antibody in a Phase I/II study as a monotherapy in patients with advanced solid tumors. CHS-1000 is a preclinical candidate targeting immune-suppressive mechanisms via pathway ILT4. It markets LOQTORZI (toripalimab-tpzi), a next generation PD-1 inhibitor, UDENYCA (pegfilgrastim-cbqv), a biosimilar of Neulasta, and YUSIMRY (adalimumab-aqvh), a biosimilar of Humira.

  • Revenue in USD (TTM)301.87m
  • Net income in USD-59.29m
  • Incorporated2010
  • Employees249.00
  • Location
    Coherus BioSciences IncC/O DENNIS M. LANFEAR201 REDWOOD SHORES PARKWAY, SUITE 200REDWOOD CITY 94065United StatesUSA
  • Phone+1 (650) 649-3530
  • Fax+1 (302) 655-5049
  • Websitehttps://www.coherus.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
CHRS:NMQ since
announced
Transaction
value
Surface Oncology IncDeal completed16 Jun 202316 Jun 2023Deal completed-68.65%322.80m
Data delayed at least 15 minutes, as of Jun 14 2024 21:00 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Fennec Pharmaceuticals Inc44.95m2.84m184.70m36.00184.8560.7964.944.110.03660.03661.620.11120.98781.157.52--6.25-73.437.37-84.3296.19--6.33-383.286.721.840.9087--1,284.50--32.34------
XBiotech Inc0.00-30.74m185.79m92.00--0.8876-----1.01-1.010.006.870.00----0.00-13.0831.88-13.6833.27------877.30----0.04560.00-100.00--25.36--24.30--
Trevi Therapeutics Inc0.00-33.57m186.65m25.00--2.53-----0.338-0.3380.001.050.00----0.00-34.47-47.39-38.08-54.41------------0.0017------0.2984---2.81--
Abeona Therapeutics Inc3.50m-76.66m188.22m84.00------53.78-3.20-3.200.1461-0.32240.0546--2.5441,666.67-119.62-53.22-140.83-65.81-----2,190.26-1,894.25----1.97--147.523.14-24.63---55.74--
Invivyd Inc0.00-206.82m188.52m94.00--1.06-----1.86-1.860.001.500.00----0.00-73.08---81.48----------5.77--0.00------17.68------
Greenwich Lifesciences Inc0.00-9.24m190.11m3.00--37.11-----0.719-0.7190.000.39770.00----0.00-106.03-36.43-109.97-38.31------------0.00-------13.63------
Coherus Biosciences Inc301.87m-59.29m193.89m249.00------0.6423-0.7801-0.78012.86-0.72110.51783.171.71986,506.60-10.17-21.43-23.51-29.3241.4679.01-19.64-36.561.05-3.871.21--21.89--18.46---18.37--
Zevra Therapeutics Inc28.01m-50.90m194.62m65.00--3.99--6.95-1.34-1.340.75131.170.2172--3.47430,876.90-39.48-32.11-47.94-39.8951.11---181.75-128.42----0.4683--170.26---72.00--69.75--
P3 Health Partners Inc1.35bn-67.27m197.26m400.00--0.5083--0.1458-0.5855-0.585511.861.231.57--11.403,381,965.00-21.31---90.11--1.590.1781-13.57-56.93---10.050.2368--20.6770.5878.61---11.20--
ASP Isotopes Inc1.27m-19.62m201.88m76.00--18.02--158.53-0.5335-0.53350.03440.21640.0425----16,755.00-65.49---81.59--32.81---1,542.66-----17.390.633-------229.34------
Biomea Fusion Inc0.00-127.27m202.73m110.00--1.50-----3.57-3.570.003.770.00----0.00-90.54---107.35--------------0.00-------43.29------
Ventyx Biosciences Inc0.00-192.60m203.04m74.00--0.6613-----3.24-3.240.004.350.00----0.00-53.41---55.81--------------0.00-------77.97------
2Seventy Bio Inc71.20m-223.22m203.05m274.00--0.9788--2.85-4.34-4.341.394.040.1136--2.68259,857.70-35.62---40.00--77.6891.76-313.51-223.57----0.00--9.7212.9614.39---22.88--
Rani Therapeutics Holdings Inc0.00-33.08m203.19m140.00--26.27-----1.29-1.290.000.15340.00----0.00-87.80---140.92-------------28.750.6695-------11.06------
Data as of Jun 14 2024. Currency figures normalised to Coherus BioSciences Inc's reporting currency: US Dollar USD

Institutional shareholders

42.97%Per cent of shares held by top holders
HolderShares% Held
Rubric Capital Management LPas of 31 Mar 202410.40m9.16%
The Vanguard Group, Inc.as of 31 Mar 20249.90m8.72%
BlackRock Fund Advisorsas of 31 Mar 20248.80m7.76%
Temasek Holdings Pte Ltd. (Investment Management)as of 20 May 20246.22m5.48%
Citadel Advisors LLCas of 31 Mar 20242.63m2.32%
Morgan Stanley & Co. LLCas of 31 Mar 20242.63m2.32%
Geode Capital Management LLCas of 31 Mar 20242.20m1.94%
Barclays Bank Plc (Private Banking)as of 31 Mar 20242.05m1.81%
SSgA Funds Management, Inc.as of 31 Mar 20242.00m1.76%
C WorldWide Asset Management Fondsm�glerselskab A/Sas of 31 Mar 20241.93m1.70%
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.